Why is NOVO Nordisk charging Americans with diabetes and obesity outrageously high prices for Ozempic and Wegovy? : hearing before the Committee on Health, Education, Labor and Pensions, United States Senate, One Hundred Eighteenth Congress, second session, September 24, 2024.
| Author/creator | United States |
| Format | Electronic |
| Publication | Washington : U.S. Government Publishing Office, 2025. |
| Description | 1 online resource (iii, 202 pages) : illustrations (some color), maps. |
| Supplemental Content | https://purl.fdlp.gov/GPO/gpo246684 |
| Supplemental Content | Address at time of PURL creation |
| Subjects |
| Series | S. hrg. ; 118-473 United States. Congress. Senate. S. hrg. ; 118-473. http://id.loc.gov/authorities/names/n83707917 ^A500722 |
| General note | Access ID (govinfo): . |
| General note | In scope of the U.S. Government Publishing Office Cataloging and Indexing Program (C&I) and Federal Depository Library Program (FDLP). |
| Bibliography note | Includes bibliographical references. |
| Performer | Hearing witnesses: Jergensen, Lars Fruergaard, President and Chief Executive Officer, Novo Nordisk, Bagsvaerd, Denmark. |
| Date/time/place of a event note | Date of hearing: 2024-09-24. |
| Source of description | Description based on online resource; title from PDF caption (GovInfo, viewed July 07, 2025). |
| Issued in other form | Print version: United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Why is NOVO Nordisk charging Americans with diabetes and obesity outrageously high prices for Ozempic and Wegovy? |
| Genre/form | Legislative hearings. |
| Standard identifier# | 57-255 (GPO jacket number) |
| GPO item number | 1043-C (online) |
| Govt. docs number | Y 4.L 11/4:S.HRG.118-473 |